Marinus Pharmaceuticals, Inc. (MRNS)

1,5100 +0,0600 (+4,14%) Al cierre: 04:00PM EDT

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center
Suite 500 100 Matsonford Road
Radnor, PA 19087
United States
484 801 4670
https://marinuspharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 165

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Scott N. Braunstein M.D.	CEO, President & Chairman	1,01M	N/A	1963
Mr. Steven E. Pfanstiel C.M.A., M.B.A.	COO, CFO & Treasurer	670,25k	N/A	1973
Dr. Joseph Hulihan M.D.	Chief Medical Officer	665,47k	N/A	1957
Dr. Alex Aimetti Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Sonya Weigle	Senior VP of Investor Relations, Human Resources & Corporate Affairs	N/A	N/A	N/A
Ms. Martha E. Manning Esq., J. D.	Senior VP, General Counsel & Secretary	N/A	N/A	1955
Molly Cameron	Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Dr. Kimberly A. McCormick Pharm.D.	Chief Regulatory & Quality Assurance Officer	N/A	N/A	N/A
Mr. Thomas J. Lyons	Chief Business Officer	N/A	N/A	N/A
Ms. Christina Shafer	Chief Commercial Officer	N/A	N/A	1977

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Marinus Pharmaceuticals, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 6; Tablero: 7; Derechos de los accionistas: 6; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.